Advertorial

This Bio-Pharmaceutical Company Hoping to Eradicate the Pandemic and Destroy Cancer Cells Recently Announced a Closing of $19.5 Million Private Placement Priced At-the-Market…

Sunshine Biopharma, Inc. (NASDAQ: SBFM), is a pharmaceutical and nutritional supplement company that focuses on the research and development of anticancer and anti-viral drugs.

Download Research Report

Learn More about Sunshine Biopharma, Inc. by gaining access to the latest research report




    Thanks for subscribing!
    CLICK HERE TO VIEW REPORT
    Check your email for a confirmation message.

    Sunshine Biopharma, Inc. is a client of Tradigital IR, an investor relations and communications firm. Please see our disclosures in the research report as well as on our website www.Tradigitalir.com.

    Canadian-based, Sunshine Biopharma, Inc. (NASDAQ: SBFM) is developing an anti-viral drug for Covid-19 that targets a different part of the virus which could help end the global pandemic!

    SBFM is focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, the company is engaged in the development and commercialization of science-based nutritional supplements. 

    In our world today, Covid-19 has become our new normal and even with current vaccines the virus is evolving and finding ways to live on. This is why companies like SBFM are integral to the health of humankind as their research hopes to eradicate the pandemic by attacking a completely different part of the virus!

    The anti-viral drug market size is MASSIVE and is expected to reach USD 50.02 BN by 2030 due to the development of new, improved, and more advanced formulations.

    SBFM’s anticancer drugs are also an impressive feat. The company recently announced that it has filed a provisional patent application in the United States covering the recently communicated mRNA molecules found in pre-clinical trials to be effective at destroying cancer cells grown in culture.

    The oncology market size is expected to be worth around US$ 536.01 billion by 2029 from USD 286.04 billion in 2021 and growing at a CAGR of 8.2% from 2021 to 2030!

    Just a few months ago, SBFM reported exciting and successful results of their mRNA molecules and their ability to destroy cancer cells grown in culture, this skyrocketed their shares and just goes to show this company has an exciting future ahead!

    “We are excited about this potential intellectual property position we just staked in connection with our ongoing mRNA-as-therapeutic-agents research. We believe the potential use of mRNA to treat human diseases opens the door to vast therapeutic possibilities for patients.”

    Dr. Steve Slilaty, CEO of SBFM

    Sunshine Biopharma, Inc. (NASDAQ: SBFM) recently announced its closing of $19.5 Million Private Placement Priced At-the-Market and with their successful anticancer drugs and exciting antivirals they could soon rise to the top of their industry!

    HIGHLIGHTS:
    • Only months ago, the company announced its closing of $19.5 Million Private Placement Priced At-the-Market.
    • SBFM is set on helping eradicate the world of the Covid-19 pandemic with their anti-viral drug. Their anti-viral targets a completely different part of the virus which makes them an exciting player in the bio-pharma industry to keep your eye on.
    • The market size for antivirals has grown a lot in recent years which can be attributed to the global pandemic as well as newer technology that can develop more advanced formulations. The anti-viral market size is expected to reach USD 50.02 BN by 2030.
    • The company recently announced that it has filed a provisional patent application in the United States covering the recently communicated mRNA molecules found in pre-clinical trials to be effective at destroying cancer cells grown in culture. This exciting piece of success skyrocketed the companies shares.
    • The oncology market size is expected to be worth around US$ 536.01 billion by 2029, from valued at USD 286.04 billion in 2021 and growing at a CAGR of 8.2% from 2021 to 2030!
    • The company also has developed nutritional supplements which are for sale in Canada and the US on Amazon. The global dietary supplements market size was valued at USD 151.9 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 8.9% from 2022 to 2030.

    Sunshine Biopharma, Inc. (NASDAQ: SBFM), a pharmaceutical and nutritional supplement company that focuses on the research and development of anticancer and anti-viral drugs, is quickly rising to the top of the bio-pharma industry!

    THE STORY

    Headquartered in Pointe-Claire, Canada, Sunshine Biopharma, Inc. (NASDAQ: SBFM), is a pharmaceutical and nutritional supplement company that focuses on the research and development of anticancer and anti-viral drugs. 

    The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. 

    It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4.

    COVID-19 TREATMENT
    • On May 22, 2020, the company filed a patent application in the United States for a new treatment for Coronavirus infection. Their patent application covers composition subject matter pertaining to small molecules to inhibit the Coronavirus proteases.
    •  In August 2020, they completed the synthesis of four different potential inhibitors of Coronavirus protease. These compounds are based on the technology described in our patent application filed on May 22, 2020.
    • In September 2020, they completed the screening of our four compounds and subsequently identified a lead Anti-Coronavirus drug candidate, SBFM-PL4.
    • The company recently expanded their research efforts into finding additional PLpro inhibitors by entering into a collaboration agreement with the University of Arizona. The collaboration is focused on determining in vivo safety, pharmacokinetics, dose selection, and mice efficacy studies of three University of Arizona owned PLpro inhibitors. The Company holds the first option to negotiate for a commercial, royalty-bearing license for all intellectual property developed by University of Arizona under the collaboration.

    The company’s treatment, SBFM-PL4, targets a completely different part of the virus and as such represents an important additional tool that could help end the pandemic!

    ONCOLOGY DRUG DEVELOPMENT

    Adva-27a:

    The company’s flagship anticancer compound is Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer. The mechanism by which Adva-27a can destroy cancer cells is through the inhibition of a key cell-cycle enzyme called Topoisomerase II. 

    Unlike other antitumor drugs currently in use, Adva-27a can destroy multidrug resistant cancer cells. Adva-27a is very effective against multidrug resistant breast cancer cells, while Etoposide, another Topoisomerase II inhibitor, has no activity against this aggressive form of cancer. In other studies, Adva-27a showed cell killing activity in various other types of multidrug resistant cancer cells.

    Preclinical studies to date have shown that:

    • Adva-27a is effective at killing different types of multidrug resistant cancer cells, including:
      • Breast Cancer Cells 
      • Small Cell Lung Cancer Cells 
      • Uterine Cancer 
      • Pancreatic Cancer 
    • Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.
    • Adva-27a has excellent clearance time as indicated by human microsomes stability studies and pharmacokinetics data in rats.
    • Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.
    • Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 13.7 micromolar. .
    • Adva-27a has shown an excellent pharmacokinetic profile, as indicated by studies done in rats.
    • Adva-27a does not inhibit tubulin assembly.

    Anticancer K1.1 mRNA

    • K1.1 is an mRNA that encodes an inhibitor of a transcription factor essential for initiation of cell division
    • They have recently shown that K1.1 mRNA can destroy cancer cells in vitro including breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2)
    • Tests conducted using non-transformed (normal) cells (HMEC) showed that these K1.1 mRNA had little cytotoxic effects
    • K1.1 mRNA is readily adaptable for delivery into patients using the mRNA vaccine technology
    • In April 2022, they filed a provisional patent application in the United States covering the K1.1 mRNA molecules and uses thereof
    • Next, the company plans to conduct mice xenograft studies to test the efficacy of K1.1 mRNA in vivo
    Essential 9™

    Essential Amino Acids are 9 out of 20 amino acids required for protein synthesis. Proteins are involved in all body functions. However, like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet.

    Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain, weakened immune system, and generally reduced wellness.

    Sunshine Biopharma’s Essential 9™ provides all 9 Essential Amino Acids ready for absorption, free-form and in the proportions recommended by Health Canada. Essential 9™ contains the exact constituents of the scientifically proven set of essential amino acids.

    Essential 9™ is available in the US on Amazon.com and in Canada on Amazon.ca

    THE BOTTOM LINE

    SBFM is focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, the company is engaged in the development and commercialization of science-based nutritional supplements. 

    With the pandemic still ongoing, SBFM is integral to the health of humankind as their research hopes to eradicate the pandemic by attacking a completely different part of the virus. 

    SBFM also recently reported exciting and successful results of their mRNA molecules and their ability to destroy cancer cells grown in culture, this news skyrocketed their shares. 

    Sitting in multiple billion-dollar markets, there’s no denying that SBFM’s momentum is unstoppable as they change the face of the Bio-Pharma industry!

    HURRY AND START YOUR RESEARCH TODAY!

    Sunshine Biopharma, Inc. is a client of Tradigital IR, an investor relations and communications firm. Please see our disclosures in the research report as well as on our website www.Tradigitalir.com.

    NO INVESTMENT ADVICE

    TraDigital IR is a publisher. You understand and agree that no content published on this site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is..

    In exchange for publishing services rendered by TraDigital IR on behalf of the client named herein, including the promotion by said company in any content on this site, TraDigital IR received compensation for such.

    This website is wholly owned by scd media llc (d/b/a “smallcapsdaily.com”). Our reports are advertorials and are for general information purposes only.   Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our services, joining our email list, as well as any social networking platforms we may use. Please note as well: Small Caps Daily and its employees are not  Registered Investment Advisors, broker-dealers, or member(s) of any association for other research providers in any jurisdiction whatsoever. release of liability: through use of this website, viewing or using you agree to hold Small Caps Daily, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Small Caps Daily encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the company profiled or is available from public sources and Small Caps Daily makes no representations, warranties, or guarantees as to the accuracy or completeness of the disclosure by the profiled company. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Small Caps Daily strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Small Caps Daily’s full disclosure is to be read and fully understood before using Small Caps Daily's website, or joining Small Caps Daily's email or text list. From time to time, Small Caps Daily will disseminate information about a company via website, email, sms, and other points of media. By viewing Small Caps Daily's website and/or reading Small Caps Daily's email or text newsletter you are agreeing to this ----> https://smallcapsdaily.com/disclaimer/. All potential percentage gains discussed in any communications are based on calculations from the low to the high of the day. We are engaged in the business of marketing and advertising companies for monetary compensation.  In compliance with section 17(b) of the securities act we are disclosing that we have been compensated a fee pursuant to an agreement between scd media llc and sea path advisory. Small Caps Daily was hired for a period beginning February 2022 and ending August 2022 to publicly disseminate information about Sunshine Biopharma, Inc. via website, email, and sms. We were paid five thousand usd via ACH. We are also disclosing that Tradigital Marketing Group has been compensated a fee pursuant to an agreement between Tradigital and Sunshine Biopharma, Inc. Tradigital was hired for a period beginning February 2022 and ending August 2022 to publicly disseminate information about Sunshine Biopharma, Inc., via website, email, and SMS. Tradigital was paid one hundred forty thousand USD via ACH.  Tradigital owns twenty thousand restricted common shares of Sunshine Biopharma, Inc., which are eligible for sale on 08/15/2022.  For the purpose of this disclaimer, we suggest that you assume we will sell all of our shares once the restriction is lifted on 08/15/2022. Readers are advised to review sec periodic reports: forms 10-q, 10k, form 8-k, insider reports, forms 3, 4, 5 schedule 13d. Small Caps Daily is compliant with the can-spam act of 2003. Small Caps Daily does not offer investment advice or analysis, and Small Caps Daily further urges you to consult your own independent tax, business, financial, and investment advisors. investing in micro-cap, small-cap, and growth securities is highly speculative and carries an extremely high degree of risk. it is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.the private securities litigation reform act of 1995 provides investors a safe harbor in regard to forward-looking statements. any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events, or performance are not statements of historical fact may be forward-looking statements. forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. understand there is no guarantee past performance will be indicative of future results in preparing this publication, Small Caps Daily has relied upon information supplied by its clients, as well as its clients’ publicly available information and press releases which it believes to be reliable; however, such reliability can not be guaranteed. investors should not rely on the information contained on this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. the advertisements in this website are believed to be reliable, however, Small Caps Daily and its owners, affiliates, subsidiaries, officers, directors, representatives, and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Small Caps Daily is not responsible for any claims made by the companies advertised herein, nor is Small Caps Daily responsible for any other promotional firm, its program, or its structure. Small Caps Daily is not affiliated with any exchange, electronic quotation system, the securities exchange commission, or finra.